Voveran TPM gel (tpm/diclofenac) / Avecho Biotech, Novartis, Nippon Zoki - LARVOL DELTA

The Role of Pharmacogenetics in Sarcoidosis (ATS 2019) - "Medications activity were determined by detecting SNPs within the following genes: SLCO1B1 (methotrexate), NUDT15 and TPMT (azathioprine), CYP3A4/5 (tacrolimus, sirolumus, and cyclosporine), CYP1A2, CYP3A4/5, CYP2C19, CYP2C9 and CYP2D6 (quinine), CYP2C9 and CYP3A4/5 (diclofenac, meloxicam, celecoxib, piroxicam, flurbiprofen), CYP2D6 (dextromethorphan) CYP3A4/5 and CYP1A2 (salmeterol and indacaterol), CYP2C9 and CYP3A4/5 (sildenafil and tadalafil), CYP3A4/5 (colchicine), CYP2C19 and CYP3A4/5 (omeprazole, lansoprazole, dexlansoprazole, esomeprazole, pantoprazole, rabeprazole) and COMT (nicotine).Results A total of 50 patients underwent pharmacogenetic evaluation. The remainder 52% had multiorgan invovlement.The highest moderate gene-drug interaction was found in nicotine (74%), dextromethorphan (60%), dexlansoprazole (48%), omeprazole, esomeprazole, pantoprazole and lansoprazole (42%).The lowest moderate gene-drug interaction was observed in azathioprine (0%),..."

Biomarker